In this case study, Novartis, a pharmaceutical company founded in 1996 and pioneer of cancer treatments Gleevec and CAR-T, partnered with MIT to solve biomanufacturing’s biggest bottleneck: batch processing. In 10 years, the alliance achieved what neither could alone: transitioning an industry from batch to continuous flow processing, cutting costs 30–50%, and earning the first FDA approval for continuous drug production. We evaluated this partnership to help your team structure similarly transformative alliances.
1. Executive Summary
Novartis partnered with MIT to solve a problem that off-the-shelf equipment couldn’t: pharmaceutical batch manufacturing was slow, capital-intensive, and structurally hard to shrink. The two sides committed to a 10-year, $65 million alliance to develop continuous flow manufacturing — replacing multi-step batch production with a single, uninterrupted process. The result was a 30–50% reduction in total production costs, a smaller manufacturing footprint, and the first-ever FDA approval of a continuous manufacturing line, granted to Novartis in 2016.
- Subject: Novartis (pharmaceutical manufacturer) and MIT (academic research partner)
- Problem: High-cost, slow, large-footprint batch drug production
- Solution: 10-year, $65M joint center developing continuous manufacturing technology
- Result: 30–50% cost reduction and industry-first FDA approval (2016)
2. The Challenge
Batch pharmaceutical manufacturing requires large facilities, long cycle times, and high capital investment, and the industry had largely optimized batch processing as far as it could go without a structural rethink. Novartis needed a fundamentally different production method, but no vendor or internal team had the deep chemical engineering expertise to build one from scratch.
- Facility cost: Batch factories carry large physical footprints and capital expenditure
- Technical ceiling: Standard process improvements couldn’t deliver step-change cost or speed gains
- Expertise gap: The fundamental engineering breakthroughs needed lived in academia, not industry
Incremental fixes to existing batch lines had plateaued — closing the gap required new science, not new software, which is what triggered a long-horizon academic alliance rather than a vendor contract.
3. The Strategy
Rather than licensing existing technology or running a short-term pilot, Novartis and MIT built a 10-year joint research center with flat, unconditional annual funding — a deliberate departure from typical milestone-based corporate R&D spending.
- Long-horizon funding: $6.5M/year for 10 years, with no product milestones attached, giving researchers room to pursue fundamental breakthroughs rather than quick wins
- Staged risk management: The technology was proven first on simple small-molecule drugs before any attempt to scale to complex biologics
- Joint governance: A steering committee with equal Novartis and MIT leadership kept research aligned with commercial timelines without dictating academic direction
Resources were split by comparative strength: MIT contributed research infrastructure and 20+ faculty across Chemical Engineering, Mechanical Engineering, and Materials Science; Novartis contributed industrial scale, funding, and real pilot manufacturing environments to test the science under commercial conditions.
4. The Results
The center delivered a validated, commercially deployed alternative to batch manufacturing.
- 30–50% reduction in total drug production costs
- Smaller facility footprint and lower capital expenditure versus traditional batch plants
- First-ever FDA approval of a continuous manufacturing line (Triamcinolone Acetonide, 2016)
- Industry-wide adoption, including the commercial spin-off Continuus Pharmaceuticals
These results didn’t stay confined to one drug line. Together, MIT and Novartis established continuous manufacturing as a viable, FDA-recognized production standard, directly resolving the cost and footprint problems the partnership was built to fix.
5. The Melan Approach
Melan advises pursuing alliances like this one when the capability gap is scientific, not operational — no internal team or vendor can be hired fast enough to close it, but a long-funded academic partner can.
- Governance model: Joint steering committee, shared IP on joint inventions, and a standing technology-transfer advisory board reviewing inventions quarterly
- Risk allocation: A first-option license clause for Novartis, paired with preserved academic publication rights for MIT — the specific structure that avoided IP gridlock here
- Shared goal: Co-develop technology that neither partner could produce alone, then commercialize it through pre-negotiated spin-off pathways
This co-investment, joint-governance model is what let the partnership move at the pace of a corporate project while retaining the depth of academic research — a combination a standard vendor contract or grant could not have achieved.
Ready to begin a pharmaceutical manufacturing partnership?
Melan helps pharma and biotech companies structure long-horizon R&D alliances that reduce production costs and navigate FDA regulatory pathways.
Evaluated using Melan’s partnership assessment framework, for informational purposes. Novartis-MIT CCM is the property of its respective partners.
